Nathanael Gray, PhD

Nancy Lurie Marks Professor of Biological Chemistry and Molecular Pharmacology in the Field of Medical Oncology, Dana-Farber Cancer Institute
Corrigendum: SIKs control osteocyte responses to parathyroid hormone.
Authors: Authors: Wein MN, Liang Y, Goransson O, Sundberg TB, Wang J, Williams EA, O'Meara MJ, Govea N, Beqo B, Nishimori S, Nagano K, Brooks DJ, Martins JS, Corbin B, Anselmo A, Sadreyev R, Wu JY, Sakamoto K, Foretz M, Xavier RJ, Baron R, Bouxsein ML, Gardella TJ, Divieti-Pajevic P, Gray NS, Kronenberg HM.
Nat Commun
View full abstract on Pubmed
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.
Authors: Authors: Zhang T, Kwiatkowski N, Olson CM, Dixon-Clarke SE, Abraham BJ, Greifenberg AK, Ficarro SB, Elkins JM, Liang Y, Hannett NM, Manz T, Hao M, Bartkowiak B, Greenleaf AL, Marto JA, Geyer M, Bullock AN, Young RA, Gray NS.
Nat Chem Biol
View full abstract on Pubmed
Discovery of a Highly Selective STK16 Kinase Inhibitor.
Authors: Authors: Liu F, Wang J, Yang X, Li B, Wu H, Qi S, Chen C, Liu X, Yu K, Wang W, Zhao Z, Wang A, Chen Y, Wang L, Gray NS, Liu J, Zhang X, Liu Q.
ACS Chem Biol
View full abstract on Pubmed
YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers.
Authors: Authors: Galli GG, Carrara M, Yuan WC, Valdes-Quezada C, Gurung B, Pepe-Mooney B, Zhang T, Geeven G, Gray NS, de Laat W, Calogero RA, Camargo FD.
Mol Cell
View full abstract on Pubmed
Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.
Authors: Authors: Nonami A, Sattler M, Weisberg E, Liu Q, Zhang J, Patricelli MP, Christie AL, Saur AM, Kohl NE, Kung AL, Yoon H, Sim T, Gray NS, Griffin JD.
Blood
View full abstract on Pubmed
Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R.
Authors: Authors: Weisberg E, Nonami A, Chen Z, Nelson E, Chen Y, Liu F, Cho H, Zhang J, Sattler M, Mitsiades C, Wong KK, Liu Q, Gray NS, Griffin JD.
Clin Cancer Res
View full abstract on Pubmed
Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?
Authors: Authors: Zhao Z, Wu H, Wang L, Liu Y, Knapp S, Liu Q, Gray NS.
ACS Chem Biol
View full abstract on Pubmed
Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs.
Authors: Authors: Tannous BA, Kerami M, Van der Stoop PM, Kwiatkowski N, Wang J, Zhou W, Kessler AF, Lewandrowski G, Hiddingh L, Sol N, Lagerweij T, Wedekind L, Niers JM, Barazas M, Nilsson RJ, Geerts D, De Witt Hamer PC, Hagemann C, Vandertop WP, Van Tellingen O, Noske DP, Gray NS, Würdinger T.
J Natl Cancer Inst
View full abstract on Pubmed
Evaluation of ERK as a therapeutic target in acute myelogenous leukemia.
Authors: Authors: Weisberg E, Meng C, Case A, Sattler M, Tiv HL, Gokhale PC, Buhrlage S, Wang J, Gray N, Stone R, Liu S, Bhagwat SV, Tiu RV, Adamia S, Griffin JD.
Leukemia
View full abstract on Pubmed
Discovery of Covalent CDK14 Inhibitors with Pan-TAIRE Family Specificity.
Authors: Authors: Ferguson FM, Doctor ZM, Ficarro SB, Browne CM, Marto JA, Johnson JL, Yaron TM, Cantley LC, Kim ND, Sim T, Berberich MJ, Kalocsay M, Sorger PK, Gray NS.
Cell Chem Biol
View full abstract on Pubmed